{"id":"intravenous-linezolid","safety":{"commonSideEffects":[{"rate":"2-3%","effect":"Thrombocytopenia"},{"rate":"1-2%","effect":"Anemia"},{"rate":"3-10%","effect":"Nausea"},{"rate":"2-11%","effect":"Diarrhea"},{"rate":"0.5-2%","effect":"Headache"},{"rate":"0.3-2%","effect":"Peripheral neuropathy"},{"rate":"<1%","effect":"Optic neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Linezolid is an oxazolidinone antibiotic that binds to the bacterial 23S rRNA component of the 50S ribosomal subunit, blocking the formation of the initiation complex and preventing translation. This mechanism is effective against both gram-positive and gram-negative bacteria, including many resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).","oneSentence":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:44.009Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gram-positive bacterial infections including MRSA and VRE"},{"name":"Nosocomial pneumonia"},{"name":"Complicated skin and soft tissue infections"},{"name":"Community-acquired pneumonia"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT07435051","phase":"PHASE3","title":"Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-05-01","conditions":"Osteomyelitis (Refractory)","enrollment":280},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT04310930","phase":"PHASE2, PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","enrollment":300},{"nctId":"NCT06423898","phase":"PHASE4","title":"Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-09","conditions":"Endocarditis, Infective","enrollment":284},{"nctId":"NCT05944458","phase":"PHASE4","title":"Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2023-08-01","conditions":"Linezolid, Antioxidant, Thrombocytopenia","enrollment":250},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":"Staphylococcus Aureus Bacteremia","enrollment":290},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":"Endocarditis","enrollment":20},{"nctId":"NCT00501150","phase":"NA","title":"Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2005-09","conditions":"Gram-positive Bacterial Infections, Staphylococcal Infections","enrollment":211},{"nctId":"NCT05293132","phase":"PHASE2, PHASE3","title":"Effect of Montelukast Versus Co Enzyme in Sepsis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-02-01","conditions":"Sepsis","enrollment":90},{"nctId":"NCT05813951","phase":"NA","title":"Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-12-02","conditions":"Treatment Efficacy","enrollment":140},{"nctId":"NCT05339802","phase":"PHASE2","title":"A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-02-16","conditions":"Skin Infection","enrollment":90},{"nctId":"NCT04531332","phase":"NA","title":"Continuous Infusion of Linezolid Versus Intermittent Dosing in the Treatment of Nosocomial Pneumonia","status":"UNKNOWN","sponsor":"October 6 University","startDate":"2019-11-15","conditions":"Pneumonia","enrollment":169},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT03405064","phase":"PHASE3","title":"Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2017-08-25","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":501},{"nctId":"NCT02679573","phase":"PHASE3","title":"Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2016-12-14","conditions":"Community Acquired Bacterial Pneumonia","enrollment":860},{"nctId":"NCT02426918","phase":"PHASE2","title":"Study of Debio 1450 for Bacterial Skin Infections","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2015-05","conditions":"Bacterial Infections","enrollment":330},{"nctId":"NCT02559310","phase":"PHASE3","title":"Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia","status":"COMPLETED","sponsor":"Nabriva Therapeutics AG","startDate":"2015-09","conditions":"Community Acquired Pneumonia","enrollment":551},{"nctId":"NCT01283581","phase":"PHASE2","title":"A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2011-01","conditions":"Skin and Subcutaneous Tissue Bacterial Infections","enrollment":256},{"nctId":"NCT01967225","phase":"PHASE3","title":"Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-11-23","conditions":"Skin Diseases, Infectious","enrollment":125},{"nctId":"NCT02168816","phase":"PHASE2","title":"Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis","status":"TERMINATED","sponsor":"Loyola University","startDate":"2014-03-19","conditions":"Osteomyelitis","enrollment":30},{"nctId":"NCT02732327","phase":"PHASE2","title":"Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2016-05-17","conditions":"Neoplasms, Febrile Neutropenia","enrollment":2},{"nctId":"NCT02066402","phase":"PHASE3","title":"Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-04","conditions":"Bacterial Infections","enrollment":598},{"nctId":"NCT00633152","phase":"PHASE2","title":"Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-02","conditions":"Bacterial Infection","enrollment":150},{"nctId":"NCT00925093","phase":"PHASE1","title":"Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection","status":"WITHDRAWN","sponsor":"Aarhus University Hospital","startDate":"2011-09","conditions":"Neurosurgery","enrollment":""},{"nctId":"NCT00229008","phase":"PHASE3","title":"Ceftobiprole in Hospital Acquired Pneumonia","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2005-11","conditions":"Pneumonia","enrollment":106},{"nctId":"NCT00210964","phase":"PHASE3","title":"Ceftobiprole in Hospital Acquired Pneumonia","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2005-04","conditions":"Pneumonia","enrollment":781},{"nctId":"NCT00084266","phase":"PHASE4","title":"Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-10","conditions":"Methicillin Resistant Staphylococcus Aureus (MRSA)","enrollment":1225},{"nctId":"NCT00795145","phase":"PHASE1","title":"A Study To Assess The Effect Of Linezolid On QTc Interval","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-12","conditions":"Bacterial Infections","enrollment":49},{"nctId":"NCT00035425","phase":"PHASE3","title":"Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-11","conditions":"Febrile Neutropenia","enrollment":120},{"nctId":"NCT00255996","phase":"PHASE1","title":"Evaluation Of Linezolid Pk Profile In Burns Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-05","conditions":"Burns","enrollment":16},{"nctId":"NCT00299520","phase":"PHASE3","title":"Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)","status":"COMPLETED","sponsor":"Arpida AG","startDate":"2005-06","conditions":"Complicated Skin and Skin Structure Infection","enrollment":""},{"nctId":"NCT00303550","phase":"PHASE3","title":"Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)","status":"COMPLETED","sponsor":"Arpida AG","startDate":"2006-03","conditions":"Skin Diseases, Bacterial","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intravenous linezolid","genericName":"Intravenous linezolid","companyName":"Arpida AG","companyId":"arpida-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Used for Gram-positive bacterial infections including MRSA and VRE, Nosocomial pneumonia, Complicated skin and soft tissue infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}